<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685993</url>
  </required_header>
  <id_info>
    <org_study_id>LPCN 1144-20-002</org_study_id>
    <nct_id>NCT04685993</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial</brief_title>
  <official_title>An Open Label Extension Study of the Safety and Tolerability of LPCN 1144 for the Treatment of Subjects With Nonalcoholic Steatohepatitis (NASH) Who Have Completed the LPCN 1144-18-002 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lipocine Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lipocine Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label extension to Study LPCN 1144-18-002. The study is aimed at evaluating&#xD;
      the safety and tolerability of LPCN 1144 in adult men with NASH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label extension protocol to provide LPCN 1144, an investigational&#xD;
      drug, to subjects with NASH who have completed the LPCN 1144-18-002 protocol. Enrolled&#xD;
      subjects will be given LPCN 1144 for up to 36 weeks. Subjects will be seen periodically to&#xD;
      evaluate safety clinical laboratory tests, tolerability of LPCN 1144, adverse events, and&#xD;
      overall subject health. Subjects will be given the option of having a liver biopsy performed&#xD;
      at Week 36.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the safety and tolerability of LPCN 1144 by assessing the number of treatment-related adverse events</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Monitor the safety and tolerability of LPCN 1144</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the effect of LPCN 1144 on liver injury markers</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Monitor the safety and tolerability of LPCN 1144</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the effect of LPCN 1144 on serum lipid panels</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Monitor the safety and tolerability of LPCN 1144</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the effect of LPCN 1144 on hematology panels</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Monitor the safety and tolerability of LPCN 1144</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the safety and tolerability of LPCN 1144 by assessing changes in patient-reported disease severity using the PGI-S questionnaire</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Monitor the safety and tolerability of LPCN 1144</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LPCN 1144</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LPCN 1144</intervention_name>
    <description>Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who have completed the 38 week study LPCN 1144-18-002 and wish to be treated&#xD;
             with LPCN 1144&#xD;
&#xD;
          2. Subject must sign the Informed Consent Form to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has participated or is participating in any other clinical (investigational) study&#xD;
             after completion of LPCN 1144-18-002 study&#xD;
&#xD;
          2. Subjects who are currently receiving any androgens or estrogens&#xD;
&#xD;
          3. Subjects who are not willing to use adequate contraception for the duration of the&#xD;
             study&#xD;
&#xD;
          4. Use of drugs historically associated with NAFLD (amiodarone, methotrexate, systemic&#xD;
             glucocorticoids, tetracyclines, tamoxifen, estrogens, anabolic steroids, valproic&#xD;
             acid, other known hepatotoxins) for more than 2 weeks in the 2 years prior to&#xD;
             enrollment&#xD;
&#xD;
          5. Any other condition, which in the opinion of the investigator would impede compliance&#xD;
             or hinder completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>R&amp;H Clinical Research</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research - Gut Whisperer</name>
      <address>
        <city>Riverton</city>
        <state>Utah</state>
        <zip>84065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Granger Medical Clinic</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

